Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma

REFERENCES

• Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M. Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma. Cancer 2000; 89(5)1037–1047
   PubMed Web of Science ®Google Scholar
• Gabizon A.A., Barenholz Y., Bialer M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm. Res. 1993; 10(5)703–708
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes. Cancer Res. 1994; 54(4)987–992
   PubMed Web of Science ®Google Scholar
• Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M. Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS-Related Kaposi's Sarcoma. J. Clin. Pharmacol. 1996; 36(1)55–63
   PubMed Web of Science ®Google Scholar
• Skubitz K.M., Hamdan H., Thompson R.C. A Phase I Study of Ambulatory Continuous Infusion Chemotherapy with Cyclophosphamide, Doxorubicin, and Dacarbazine (ciCAD) for Soft Tissue Sarcomas. J. Infusional Chemother. 1992; 2: 97–105
   Google Scholar
• Zalupski M., Metch B., Balcerzak S., Fletcher W.S., Chapman R., Bonnet J.D. Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients with Soft-Tissue Sarcomas: A Southwest Oncology Group Study. J. Natl Cancer Inst. 1991; 83(13)926–932
   PubMed Web of Science ®Google Scholar
• Northfelt D.W., Dezube B.J., Thommes J.A., Levine R., Von Roenn J.H., Dosik G.M. Efficacy of Pegylated-Liposomal Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma After Failure of Standard Chemotherapy. J. Clin. Oncol. 1997; 15(2)653–659
   PubMed Web of Science ®Google Scholar
• Madhavan S., Northfelt D.W. Lack of Vesicant Injury Following Extravasation of Liposomal Doxorubicin [Letter]. J. Natl Cancer Inst. 1995; 87(20)1556–1557
   PubMed Web of Science ®Google Scholar
• Northfelt D.W. Stealth Liposomal Doxorubicin (SLD) Delivers More Doxorubicin (DOX) to AIDS-Related Kaposi's Sarcoma (AIDS-KS) Lesions Than to Normal Skin. Proc. Am. Soc. Clin. Oncol. 1994; 13: 15, (abstr)
   Google Scholar
• Symon Z., Peyser A., Tzemach D., Lyass O., Sucher E., Shezen E. Selective Delivery of Doxorubicin to Patients with Breast Carcinoma Metastases by Stealth Liposomes. Cancer 1999; 86(1)72–78
   PubMed Web of Science ®Google Scholar
• Huang S.K., Mayhew E., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and Therapeutics of Sterically Stabilized Liposomes in Mice Bearing C-26 Colon Carcinoma. Cancer Res. 1992; 52(24)6774–6781
   PubMed Web of Science ®Google Scholar
• Vaage J., Barbera-Guillem E., Abra R., Huang A., Working P. Tissue Distribution and Therapeutic Effect of Intravenous Free or Encapsulated Liposomal Doxorubicin on Human Prostate Carcinoma Xenografts. Cancer 1994; 73(5)1478–1484
   PubMed Web of Science ®Google Scholar
• Planting A.S., van der Burg M.E., Goey S.H., Schellens J.H., van den Bent M.J., de Boer-Dennert M. Phase II Study of a Short Course of Weekly High-Dose Cisplatin Combined with Long-Term Oral Etoposide in Pleural Mesothelioma. Ann. Oncol. 1995; 6(6)613–615
   PubMed Web of Science ®Google Scholar
• Harvey V.J., Slevin M.L., Ponder B.A., Blackshaw A.J., Wrigley P.F. Chemotherapy of Diffuse Malignant Mesothelioma. Phase II Trials of Single-Agent 5-Fluorouracil and Adriamycin. Cancer 1984; 54(6)961–964
   PubMed Web of Science ®Google Scholar
• Zidar B.L., Metch B., Balcerzak S.P., Pierce H.I., Militello L., Keppen M.D. A Phase II Evaluation of Ifosfamide and Mesna in Unresectable Diffuse Malignant Mesothelioma. A Southwest Oncology Group Study. Cancer 1992; 70(10)2547–2551
   PubMed Web of Science ®Google Scholar
• Vogelzang N.J., Herndon J.E., II, Miller A., Strauss G., Clamon G., Stewart F.M. High-Dose Paclitaxel Plus G-CSF for Malignant Mesothelioma: Calgb Phase II Study 9234. Ann. Oncol. 1999; 10(5)597–600
   PubMed Web of Science ®Google Scholar
• Kasseyet S., Astoul P., Boutin C. Results of a Phase II Trial of Combined Chemotherapy for Patients with Diffuse Malignant Mesothelioma of the Pleura. Cancer 1999; 85(8)1740–1749
   PubMed Web of Science ®Google Scholar
• Yogelzang N.J., Herndon J.E., II, Cirrincione C., Harmon D.C., Antman K.H., Corson J.M. Dihydro-5-Azacytidine in Malignant Mesothelioma. A Phase II Trial Demonstrating Activity Accompanied by Cardiac Toxicity. Cancer and Leukemia Group B. Cancer 1997; 79(11)2237–2242
   PubMed Web of Science ®Google Scholar
• Sahmoud T., Postmus P.E., van Pottelsberghe C., Mattson K., Tammilehto L., Splinter T.A. Etoposide in Malignant Pleural Mesothelioma: Two Phase II Trials of the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer 1997; 33(13)2211–2215
   PubMed Web of Science ®Google Scholar
• Pennucci M.C., Ardizzoni A., Pronzato P., Fioretti M., Lanfranco C., Verna A. Combined Cisplatin, Doxorubicin, and Mitomycin for the Treatment of Advanced Pleural Mesothelioma: A Phase II FONICAP Trial. Italian Lung Cancer Task Force. Cancer 1997; 79(10)1897–1902
   PubMed Web of Science ®Google Scholar
• Chahinian A.P., Antman K., Goutsou M., Corson J.M., Suzuki Y., Modeas C. Randomized Phase II Trial of Cisplatin with Mitomycin or Doxorubicin for Malignant Mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol. 1993; 11(8)1559–1565
   PubMed Web of Science ®Google Scholar
• Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., Rudd R.M. Phase II Study of Vinorelbine in Patients with Malignant Pleural Mesothelioma [In Process Citation]. J. Clin. Oncol. 2000; 18(23)3912–3917
   PubMed Web of Science ®Google Scholar
• van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A. A Phase II Study of Gemcitabine in Patients with Malignant Pleural Mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85(12)2577–2582
   PubMed Web of Science ®Google Scholar
• O'Reilly E.M., Ilson D.H., Saltz L.B., Heelan R., Martin L., Kelsen D.P. A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. Cancer Investig. 1999; 17(3)195–200
   PubMed Web of Science ®Google Scholar
• Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M. Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study [See Comments]. J. Clin. Oncol. 1999; 17(1)25–30
   PubMed Web of Science ®Google Scholar
• Shin D.M., Fossella F.V., Umsawasdi T., Murphy W.K., Chasen M.H., Walsh G. Prospective Study of Combination Chemotherapy with Cyclophosphamide, Doxorubicin, and Cisplatin for Unresectable or Metastatic Malignant Pleural Mesothelioma [See Comments]. Cancer 1995; 76(11)2230–2236
   PubMed Web of Science ®Google Scholar
• Nakano T., Chahinian A.P., Shinjo M., Togawa N., Tonomura A., Miyake M. Cisplatin in Combination with Irinotecan in the Treatment of Patients with Malignant Pleural Mesothelioma: A Pilot Phase II Clinical Trial and Pharmacokinetic Profile. Cancer 1999; 85(11)2375–2384
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J. Clin. Oncol. 1995; 13(7)1777–1785
   PubMed Web of Science ®Google Scholar
• Legha S.S., Benjamin R.S., Mackay B., Ewer M., Wallace S., Valdivieso M. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann. Intern. Med. 1982; 96(2)133–139
   PubMed Web of Science ®Google Scholar
• Lokich J., Bothe A., Zipoli T., Green R., Sonneborn H., Paul S. Constant Infusion Schedule for Adriamycin: A Phase I–II Clinical Trial of a 30-Day Schedule by Ambulatory Pump Delivery System. J. Clin. Oncol. 1983; 1(1)24–28
   PubMed Web of Science ®Google Scholar
• Baas P., van Meerbeeck J., Groen H., Schouwink H., Burgers S., Daamen S. Caelyx in Malignant Mesothelioma: A Phase II EORTC Study [In Process Citation]. Ann. Oncol. 2000; 11(6)697–700
   PubMed Web of Science ®Google Scholar
• Oh Y., Perez-Soler R., Fossella F.V., Glisson B.S., Kurie J., Walsh G.L. Phase II Study of Intravenous Doxil in Malignant Pleural Mesothelioma [In Process Citation]. Investig. New Drugs 2000; 18(3)243–245
   PubMed Web of Science ®Google Scholar
• Skubitz K.M., Skubitz A.P. Mechanism of Transient Dyspnea Induced by Pegylated-Liposomal Doxorubicin (Doxil). Anticancer Drugs 1998; 9(1)45–50
   PubMed Web of Science ®Google Scholar